IsoTis first-half operating losses more than double

13 August 2001

In line with its own expectations, Netherlands-based biomedical companyIsoTis NV says operating losses increased to 7.1 million euros ($6.4 million) for the first six months of 2001, compared with 3.4 million euros in the like, year-earlier period. Total revenues for the half-year were up 13.6% at 1.2 million, largely due to a substantial increase in government grants, up from 670,000 euros to nearly 1.1 million euros, the firm notes.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight